Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease
about
The endocannabinoid system in normal and pathological brain ageingTargeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilitiesCannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disordersAre cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic reviewCannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's DiseaseMechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments.Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in miceCannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.The therapeutic potential of cannabinoids for movement disorders.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionCannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease.Central CB2 receptors in inflammation-driven neurodegeneration: dysregulation and therapeutic potentialMarijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity.Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.Prospects for cannabinoid therapies in basal ganglia disorders.Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?The influence of cannabinoids on generic traits of neurodegeneration.Cannabinoids: new promising agents in the treatment of neurological diseases.Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.Neuroprotective Effect of JZL184 in MPP(+)-Treated SH-SY5Y Cells Through CB2 Receptors.Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders.Brain cannabinoid receptor 2: expression, function and modulation.Molecular Pharmacology of Phytocannabinoids.Cannabinoid signaling in health and disease.Endocannabinoid system in neurodegenerative disorders.Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease.Cannabinoids in Parkinson's DiseaseThe bright side of psychoactive substances: cannabinoid-based drugs in motor diseases.Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor.Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor.Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice.Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
P2860
Q22242668-1AD76587-1AA1-410F-B437-7104668DFA37Q24623282-B62D1AC9-14C4-474E-AD1F-51F596EE80D8Q26823267-50BC66D3-3E68-47D4-B87D-15C37401F930Q27005619-C9EC0C4C-4C88-4C61-BF5C-F45C75E89737Q28277871-8837EE1C-5818-4BB3-8B1B-07C67192AC27Q30361677-8D4CBBAF-8F46-4427-BBC6-A5524039A71AQ34581274-A734E461-4906-46DC-89C1-30505A2DAC28Q34680801-3D05FDA5-8834-4755-B339-561B79021DB7Q35171113-1109EEAE-8CEF-4454-866F-FF8A15AD80FBQ35499568-1A85DDE5-F3F7-431D-A73C-5BB79088F100Q37120339-ED79FCC5-ED3D-4F91-AF56-781A821B1F9EQ37387247-D8D70873-D49A-4979-99D9-66F9AAB7A721Q37512670-C3C1C804-5646-414F-8850-410F915440EDQ37525458-3E5D591A-19A3-45ED-A978-854D96AC5AB8Q37637769-1B7A4BE6-E50C-4D14-A0E9-09F441DD7B50Q37872326-7D5422F4-99FC-4CF4-AB1C-EBA882188A55Q38012845-133FCD9B-F4E3-498F-BDF9-855D55CDD632Q38156518-CAD24CE1-D971-41E2-97D3-303E4C2DED81Q38269376-FC246426-DDEB-441D-B3BF-7F2F926928E9Q38522769-17ED5923-7136-4554-89D3-6026B0637A15Q38563981-670706BE-E30A-4221-95BA-4C71B6BDA914Q38684679-C2387883-7609-4CA6-A5CF-79627F69FE99Q38874674-84950086-5A1D-410E-9C8F-BFD75B17CCDAQ38996589-593E13E8-EA85-436D-9903-9B73BA1F4735Q39075448-12FB9817-350C-4EEA-96C6-C417C7ADAF6CQ39102188-BA4916EB-A15F-44D8-9A4B-348BFD3CACDBQ39163671-71A13385-0125-4F18-BCDF-A409EC435C1CQ39368845-A9A288E7-4ADB-4A83-991F-B7596B9916CDQ41907106-E44D2770-CF8D-4D31-A331-51A402FA1981Q42087548-42B34B4A-B1AA-475A-9E16-E81BA3BC6B2CQ42258332-AF42B3DF-1AA5-4313-BB8A-C213D394D697Q42495608-BBE72A1C-FBBB-49BD-8656-897488CAC9C2Q43162071-E88606F2-4EFB-427D-8AF2-81B2E04ABAE8Q47432979-36FC97E4-7A65-49F9-AC16-09807DE80B04Q49433973-247C2EBD-461C-4F96-9B71-4E2E05DEE967Q50688164-D897FB3E-CDBD-4EF9-BEDC-C72679009008Q55387906-00A372A7-E0DF-4921-A37B-D2A1BCF3CA6A
P2860
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Symptom-relieving and neuropro ...... models of Parkinson's disease
@ast
Symptom-relieving and neuropro ...... models of Parkinson's disease
@en
type
label
Symptom-relieving and neuropro ...... models of Parkinson's disease
@ast
Symptom-relieving and neuropro ...... models of Parkinson's disease
@en
prefLabel
Symptom-relieving and neuropro ...... models of Parkinson's disease
@ast
Symptom-relieving and neuropro ...... models of Parkinson's disease
@en
P2093
P2860
P50
P1476
Symptom-relieving and neuropro ...... models of Parkinson's disease
@en
P2093
C Palomo-Garo
J Fernández-Ruiz
P2860
P304
P356
10.1111/J.1476-5381.2011.01278.X
P407
P577
2011-08-01T00:00:00Z